H1, a healthcare data and technology company, has entered into a strategic collaboration with Novo Nordisk to develop artificial intelligence (AI)-powered solutions aimed at improving drug development processes and strengthening clinical trial operations.
The partnership will focus on creating advanced AI data models and clinical development workflows that can help Novo Nordisk make faster, more informed decisions across different stages of research. The collaboration highlights the growing role of healthcare data platforms in transforming pharmaceutical research, from identifying suitable clinical trial participants to improving study design and operational efficiency.
As pharmaceutical companies increasingly invest in digital transformation, drug discovery has become one of the key areas where AI technologies are being explored to accelerate research timelines and improve the identification of promising therapies. By combining H1’s healthcare provider data capabilities with Novo Nordisk’s pharmaceutical expertise, the companies aim to develop solutions that support more efficient innovation across the drug development lifecycle.
Under the agreement, Novo Nordisk will use H1’s AI platform to support clinical trial planning, site selection, and patient enrollment strategies. The collaboration will also involve the development of AI-ready data solutions designed to enhance clinical development workflows and provide researchers with deeper insights during decision-making.
AI Platform to Support Clinical Trial Design and Development Efficiency
H1’s platform is built around healthcare provider data and analytics capabilities that help organizations identify relevant physicians, researchers, and healthcare institutions. The company works with life sciences companies, health systems, technology firms, and healthcare organizations to improve connections between stakeholders and optimize clinical processes.
Through the new collaboration, H1 and Novo Nordisk will work together on AI models that can support clinical development activities. One major focus will be improving the way clinical trials are designed and executed, including identifying appropriate research sites and improving enrollment strategies.
Clinical trial delays and challenges in recruiting suitable participants remain significant issues for pharmaceutical companies worldwide. Selecting the right trial locations and ensuring access to appropriate patient populations can directly impact development timelines and costs. AI-based tools that analyze large healthcare datasets may help companies address these challenges by providing more precise insights during trial planning.
As part of the agreement, H1 will also acquire rights to develop Novo Nordisk’s StudyHub digital platform. Originally created by Novo Nordisk, StudyHub was designed to organize clinical trial information and improve access to data throughout the development process.
By integrating StudyHub capabilities with its own AI technology and healthcare datasets, H1 plans to further develop solutions that can support more connected and data-driven clinical workflows. The companies expect this collaboration to help reduce inefficiencies and improve decision-making throughout pharmaceutical research.
Mishal Patel, group vice president of AI and digital innovation for research and development at Novo Nordisk, said the partnership will help advance existing digital capabilities by combining Novo Nordisk’s internal innovations with H1’s technology expertise and proprietary data resources.
The collaboration reflects Novo Nordisk’s broader strategy of using digital technologies to improve research, manufacturing, commercial operations, and healthcare delivery.
Pharmaceutical Industry Accelerates AI Adoption Across Research and Development
The agreement between H1 and Novo Nordisk comes amid increasing investment by pharmaceutical companies in AI technologies designed to transform the way medicines are discovered and developed.
H1 has strengthened its position in healthcare data technology through multiple funding rounds, including a $40 million investment led by CVS Health Ventures. The company has previously raised significant capital to expand its AI platform and healthcare intelligence capabilities.
Novo Nordisk has also established several partnerships focused on applying AI across its operations. Earlier collaborations have included agreements with technology companies and AI-focused organizations to explore applications in research, manufacturing, and healthcare innovation.
The company recently expanded its AI initiatives through a collaboration with OpenAI to explore the use of advanced AI capabilities across global operations. These efforts include applications in drug research, workforce development, manufacturing optimization, commercial activities, and supply chain management.
Novo Nordisk has also worked with NVIDIA to develop customized AI models and digital tools designed to support pharmaceutical research. In another partnership with Valo Health, the company has leveraged AI technology and human datasets to discover and develop potential treatments for conditions including type 2 diabetes, cardiovascular disease, and obesity.
The growing number of pharmaceutical AI partnerships reflects a broader shift within the industry toward data-driven research models. Companies are increasingly looking beyond traditional laboratory approaches and exploring how AI can help analyze complex biological information, improve clinical trial strategies, and accelerate the development of new therapies.
For H1, the partnership with Novo Nordisk represents an opportunity to expand its healthcare intelligence platform into one of the most competitive areas of life sciences innovation. For Novo Nordisk, the collaboration strengthens its efforts to integrate AI into research and development while improving operational efficiency.
As the pharmaceutical sector continues to face pressure to reduce development timelines and bring treatments to patients faster, partnerships combining healthcare data, AI capabilities, and scientific expertise are expected to play a larger role in shaping the future of medicine development.
Ref: https://www.mobihealthnews.com/news/novo-nordisk-h1-partner-ai-drug-discovery-clinical-trials
